SciTech Development has a strong and experienced Board of Advisors comprised of pharmaceutical and biotech company executives, senior product development managers, and highly skilled clinicians and scientists. SciTech's advisory board includes: (1) Brian Leyland-Jones, MD, PhD Avera Cancer Institute, Chief Medical Officer & Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR). (2) John Doux, MD, MBA, Palo Alto Investors, Funded development of Valchlor® for Ceptaris (CTCL drug). (3) Gregory Kalemkerian, MD, Professor of Medicine, University of Michigan, small cell lung cancer specialist, experience administering fenretinide to humans, Principal Investigator for SciTech’s Phase 1 SCLC clinical trial. (4) Timothy Kuzel, MD, FACP, Professor of Medicine & Chief, Division of Hematology/Oncology/Cell Therapy, Rush University. Medical Center (Chicago), T-cell lymphoma specialist, Principal Investigator for SciTech’s Phase 1 T-cell lymphoma trial. (5) Kenneth Massey, PhD, Senior Director, Venture Development, Wayne State University, Former Director, Development Operations & Senior Scientist, Pfizer. (6) Steve Munk, PhD, Deputy Director, The Biodesign Institute, ASU, previous CEO, Ash Stevens, Inc., oncology drug manufacturing, Managed FDA manufacturing approval for notable oncology drugs: Velcade,® Clolar® & Vidaza.®

1. SciTech Development, LLC
281 Kercheval Avenue
Grosse Pointe Farms, MI 48236
T: (313) 938-5517
W: www.SciTechDevelopment.com
Board of Advisors
SciTech has a strong and experienced Board of Advisors comprised of pharmaceutical and biotech company executives,
senior product development managers, and highly skilled clinicians and scientists. They are:
• Additional Key Opinion Leaders (KOLs) are preparing to join the SciTech Team.